PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Titel:
PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Auteur:
Sharman, J. Coutre, S. Furman, R. Cheson, B. Pagel, J. Hillmen, P. Barrientos, J. Zelenetz, A. Kipps, T. Flinn, I. Ghia, P. Hallek, M. Coiffier, B. O’Brien, S. Stilgenbauer, S.